Lineage Cell Therapeutics (LCTX) Change in Account Payables (2017)

Lineage Cell Therapeutics (LCTX) posted quarterly Change in Account Payables of $428000.0 for Q3 2017, up 323.76% quarter-over-quarter from $101000.0 in Q2 2017.

Lineage Cell Therapeutics (LCTX) Change in Account Payables (2017) Analysis & Trends

Lineage Cell Therapeutics' Change in Account Payables history runs 1 years deep, the most recent figure standing at $428000.0 for Q3 2017.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Account Payables (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -66.70 Mn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - 5.03 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 37.53 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 520,137.79
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Lineage Cell Therapeutics 270.61 Mn 212.77 Mn 1.07 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2017 428,000.00
Sep 30, 2017 428,000.00
Jun 30, 2017 101,000.00
Jun 30, 2017 101,000.00
Mar 31, 2017 231,000.00
Mar 31, 2017 231,000.00